Table 2. Comparison of ORRs and DCRs between 48 mCRC patients with wild-type RAS and 25 mCRC patients with mutant-type RAS in the two groups of second-line treatment.
| Variable | Wild type of RAS gene | Mutant type of RAS gene | |||||
|---|---|---|---|---|---|---|---|
| mFOLFOX6, (N=32) (%) | mFOLFOX6 + VEGFi, (N=16) (%) | P value | mFOLFOX6, (N=16) (%) | mFOLFOX6 + VEGFi, (N=9) (%) | P value | ||
| Response | 0.003 | 0.030 | |||||
| PR | 0 (0) | 3 (18.8) | 0 (0) | 2 (22.3) | |||
| SD | 10 (31.3) | 9 (56.2) | 3 (18.8) | 4 (44.4) | |||
| PD | 22 (68.7) | 4 (25.0) | 13 (81.2) | 3 (33.3) | |||
| Responder | 0.011 | 0.049 | |||||
| Yes | 0 (0) | 3 (18.8) | 0 (0) | 2 (22.3) | |||
| No | 32 (100.0) | 13 (81.2) | 16 (100.0) | 7 (77.7) | |||
| DCR | 0.004 | 0.017 | |||||
| Yes | 10 (31.3) | 12 (75.0) | 3 (18.8) | 6 (66.7) | |||
| No | 22 (68.7) | 4 (25.0) | 13 (81.2) | 3 (33.3) | |||
ORR, objective response rate; DCR, disease control rate; mCRC, metastatic colorectal cancer; VEGFi, vascular endothelial growth factor inhibitors (aflibercept and bevacizumab); PR, partial response; SD, stable disease; PD, progressive disease. Responder: yes, partial response; no, stable disease + progressive disease.